Author

David Drobne

ASGE SOP 2019 CHOLEDOCHOLITHIASIS CRITERIA ARE NOT RELIABLE IN PATIENTS WITH ACUTE BILIARY PANCREATITIS: A SINGLE CENTER EXPERIENCE
ASGE SOP 2019 CHOLEDOCHOLITHIASIS CRITERIA ARE NOT RELIABLE IN PATIENTS WITH ACUTE BILIARY PANCREATITIS: A SINGLE CENTER EXPERIENCE

ASGE SOP 2019 CHOLEDOCHOLITHIASIS CRITERIA ARE NOT RELIABLE IN PATIENTS WITH ACUTE BILIARY PANCREATITIS: A SINGLE CENTER EXPERIENCE
ASGE SOP 2019 CHOLEDOCHOLITHIASIS CRITERIA ARE NOT RELIABLE IN PATIENTS WITH ACUTE BILIARY PANCREATITIS: A SINGLE CENTER EXPERIENCE

David Drobne  et al.

CLINICAL AND BIOMARKER REMISSION IS MAINTAINED AFTER SWITCH FROM MONTHLY DOSED VEDOLIZUMAB TO THE NOVEL SUBCUTANEOUS FORMULATION IN INFLAMMATORY BOWEL DISEASE
CLINICAL AND BIOMARKER REMISSION IS MAINTAINED AFTER SWITCH FROM MONTHLY DOSED VEDOLIZUMAB TO THE NOVEL SUBCUTANEOUS FORMULATION IN INFLAMMATORY BOWEL DISEASE

David Drobne  et al.

REAL-LIFE EFFECTIVENESS OF TOFACITINIB IN TWO INDICATIONS IN ULCERATIVE COLITIS: A RETROSPECTIVE WORLDWIDE, MULTICENTER, COLLABORATIVE STUDY
REAL-LIFE EFFECTIVENESS OF TOFACITINIB IN TWO INDICATIONS IN ULCERATIVE COLITIS: A RETROSPECTIVE WORLDWIDE, MULTICENTER, COLLABORATIVE STUDY

David Drobne  et al.

Item 1 - 4 / 4
1